Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CASE REPORT
Long-term follow-up of laminin α2 (merosin)-deficient muscular dystrophy in a cat

Yuichi Awamura DVM1*, Kazuyuki Uchida DVM, PhD2, Eri Arikawa-Hirasawa MD, PhD3,4

1Totsuka Animal Hospital, 3863 Totsuka-cho, Totsuka-ku, Yokohama 244-0003, Japan
2Department of Veterinary Pathology, Faculty of Agriculture, University of Miyazaki, 1-1 Gakuen-nishi, Miyazaki 889-2155, Japan
3Research Institute for Diseases of Old Age, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
4Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Progressive muscle weakness beginning at 6 months of age was observed in a male Persian-mix cat. Muscle atrophy and joint contracture progressed over the next 3 years. The cat had developed gait difficulty at 8 months of age. The cat died at age of 5 years and 3 months due to an acute respiratory disorder. The clinical, laboratory, necropsy and histopathological findings of the cat were consistent with those of muscular dystrophy. The cat was diagnosed as having laminin α2 (merosin)-deficient muscular dystrophy on the basis of immunohistochemical findings. The cat was born in an inbred colony, and another related cat exhibited similar clinical signs. Few cases of laminin α2-deficient muscular dystrophy have been reported in cats, and this report provides additional information about the disease.

Date accepted: 30 November 2007

© 2007 ESFM and AAFP. Published by Elsevier Ltd. All rights reserved.
8 months of age (436 and 2000 U/l, respectively; reference range 87–309 U/l), but thereafter it remained within the reference range. Serum alanine aminotransferase (ALT) activity was slightly elevated at 8 and 11 months of age (113 and 122 U/l, respectively; reference range 22–84 U/l). Glucose, electrolytes and other parameters were all within the reference ranges. Serological testing (Idexx, Tokyo, Japan) showed that the cat was negative for feline leukaemia virus (FeLV) antigen, and also for antibodies against feline immunodeficiency virus (FIV), feline coronavirus (FCoV) and Toxoplasma gondii. Findings of urinalysis at 6 and 8 months and 2 years of age were unremarkable.

Echocardiography at 7 months of age demonstrated slight enlargement of the left ventricular free wall (diastolic phase 9.4 mm; reference range 2.5–5.0 mm) and ventricular septum (diastolic phase 5.4 mm; reference range 2.5–5.0 mm). Electrocardiography (ECG) at 8 months of age demonstrated a high R wave in lead II (2.0 mV; upper reference value 0.9 mV).

Biopsy of the thigh muscles was performed at 2 years and 3 months of age. Grossly, the muscle tissue was pale and resembled chicken meat. Tissue samples of the sartorius and biceps muscles of the thigh were frozen in dry ice, and cryostat sections were made. However, the results of immunohistochemical staining with monoclonal anti-human dystrophin antibody (Novocastra, Newcastle, UK) were normal.

On post-mortem examination, various degrees of muscle atrophy were observed in the general skeletal muscles, and most prominently in the pelvic limbs. The affected muscles were pale to white and resembled fatty tissue, the changes being quite severe. Similar severe to moderate atrophic muscle changes were also observed in the thoracic limbs, abdomen, lumbar paraspinal muscles and tail. The muscles in the head and neck and thoracic paraspinal muscles were relatively well preserved. The myocardium in the area of the ventricular septum and the left ventricular free wall was slightly enlarged. Diffuse haemorrhage and mild exudation were found in the lungs. No gross lesions were noted in the brain, spinal cord, peripheral nerves, tongue, oesophagus, diaphragm, urinary bladder or other viscera.

Histopathological examination was performed. The tissue samples were fixed in 10% formalin and processed routinely for paraffin sections. Severe muscle atrophy characterised by marked reduction in both the size and number of the muscle fibres and diffuse infiltration by fatty tissue, especially in the limbs, was observed. Within the muscle lesions, the intramuscular nerve branches and muscle spindles were well preserved (Fig 2). The remaining muscle fibres varied in size and showed several types of degenerative change, including endomysial fibrosis and increased numbers of nuclei with occasional central nuclei. Similar changes were also observed in the longissimus and masseter muscles and the diaphragm, although these lesions were less prominent than those in the limbs. In the heart, changes were characterised by irregular arrangement, disarray and vacuolar changes of cardiac muscle fibres, and were consistent with hypertrophic cardiomyopathy. In the lungs, there was diffuse thickening of the alveolar walls, as well as focal crystalline deposits of cholesterol and accumulation of foamy macrophages and lymphocytes. These changes were consistent with lipid pneumonia. In the nervous

![Fig 1. A castrated male Persian-mix cat at 2 years and 2 months of age. The cat is recumbent, and flexed contracture and muscle atrophy in the limbs are evident. Head and neck motion is relatively well preserved.](image)
tissues, including the brain and spinal cord, nerve roots, ganglia and peripheral nerves, no significant pathological changes were visualised in paraffin sections stained with haematoxylin and eosin and Luxol fast blue. In the urinary bladder and the other viscera, there were no remarkable histological lesions.

Immunohistochemical analysis for dystrophin, α- and β-dystroglycans, α-, β-, γ- and δ-sarcoglycans, emerin and laminin α2 was performed using unfixed cryostat sections of necropsy specimens of muscles taken from this cat, and also from three cats without clinically evident neuromuscular disorders as controls. Monoclonal antibodies (1F9 and 5H2) (provided by Eva Engvall, Burnham Institute for Medical Research, La Jolla, CA, USA), which had been characterised previously, were used for laminin α2-immunostaining (Leivo and Engvall 1988, O’Brien et al 2001). Commercially available antibodies were used to assess other muscle proteins. The results of immunohistochemistry with these antibodies, except laminin α2, were equally positive in both this cat and the control cats. However, the muscle basement membrane from this cat was unreactive with both 1F9 and 5H2 antibodies against laminin α2, whereas those of the control cats were intensely immunoreactive with both antibodies (Table 1, Fig 3). These results indicated an absence of laminin α2 in the skeletal muscles of this cat.

The dam of this cat was of pedigree Persian breed. The sire was a Persian-mix cat, which was the offspring of the same dam, and, therefore, the proband cat was the product of dam and offspring inbreeding. Two other littermates of this cat were clinically normal. However, similar clinical signs were observed in another male cat in the next litter from the same dam and sire (Fig 4). Muscle weakness and atrophy and joint contracture progressed rapidly from 6 to 9 months of age in the affected sibling, and it died suddenly at 1 year and 11 months of age. At the owner’s request, no further pathological examinations were performed.

The final diagnosis in the present cat was laminin α2 (merosin)-deficient muscular dystrophy. The results of immunohistochemistry indicated a defect of laminin α2 in the muscle basement membrane.

---

### Table 1. Results of immunohistochemical staining

| Antibody | Controls | Affected cat |
|----------|----------|--------------|
| Dystrophin (monoclonal anti-human)* | + | + |
| Dystrophin (monoclonal anti-human)† | + | + |
| α-Dystroglycan (monoclonal anti-rabbit)‡ | + | + |
| β-Dystroglycan (monoclonal anti-human)§ | + | + |
| α-Sarcoglycan (monoclonal anti-rabbit)∥ | + | + |
| β-Sarcoglycan (monoclonal anti-human)∥ | + | + |
| γ-Sarcoglycan (monoclonal anti-rabbit)∥ | + | + |
| δ-Sarcoglycan (monoclonal anti-human)∥ | + | + |
| δ-Sarcoglycan (polyclonal anti-human)¶ | + | + |
| Emerin (monoclonal anti-human)¶ | + | + |
| Laminin α2 1F9 (monoclonal anti-human)# | + | – |
| Laminin α2 5H2 (monoclonal anti-human)# | + | – |

*Chemicon International Inc, Temecula, CA, USA.
†Kamiya Biomedical Company, Seattle, WA, USA.
‡Upstate, Lake Placid, NY, USA.
§YLEM, Roma, Italy.
∥Novocastra, Newcastle, UK.
¶Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA.
#Provided by Eva Engvall, Burnham Institute for Medical Research, La Jolla, CA, USA.

*+, Positive; –, negative.
In human medicine, muscular dystrophies are described according to whether they are inherited conditions characterised by varying degrees of muscle weakness that are not neurogenic (Emery 2001a). Then whether they are associated with specific defects in proteins, which are normally expressed at least in the skeletal muscles (Emery 2001a). Finally, mitochondrial myopathies, as well as myopathies associated with characteristic pathological lesions such as central cores or nemaline rods, are excluded (Emery 2001a). Recently, muscular dystrophies have been classified into more than 30 different forms, according to whether they are due to defects in muscle proteins such as dystrophin, laminin α2, α7 integrin, dysferlin, caveolin-3, sarcoglycans, telethonin, myotilin, calpain-3, poly-A binding protein,

![Fig 3. Immunofluorescence staining of muscles for laminin α2. (a) Control with 1F9 antibody, (b) affected muscle with 1F9 antibody, (c) control with 5H2 antibody and (d) affected muscle with 5H2 antibody. The green staining indicates positivity, and the lack of staining indicates negativity with the antibodies. The basement membranes of the affected muscles (b and d) are negative for the two monoclonal antibodies (1F9 and 5H2), whereas those of the controls (a and c) are intensely positive for both antibodies (bar = 100 μm).](image)

![Fig 4. Family tree. The circles and boxes indicate females and males, respectively. The clear circles and boxes indicate clinically normal cats, and the coloured boxes indicate affected cats. The present cat and its siblings were inbred. There were two affected male cats (the present case and an affected sibling), two clinically normal male cats and two clinically normal female cats.](image)
Laminins are glycoproteins which are major components of the basement membrane and consist of α, β and γ subunits (Wewer and Engvall 1996, Hayashi and Arahata 1997). Laminin α2 is one of the five subclasses of laminin α chains (Wewer and Engvall 1996, Hayashi and Arahata 1997). Laminins which include the laminin α2 chain have been called merosin and are found in the basement membranes of skeletal and cardiac muscles, Schwann cells and the placenta (Leivo and Engvall 1988, Hayashi and Arahata 1997). Muscular dystrophy caused by laminin α2 deficiency is called merosin-deficient congenital muscular dystrophy, and shows autosomal recessive inheritance in humans (Tome et al. 1994, Helbling-Leclerc et al. 1995, Hayashi and Arahata 1997, Emery 2001a).

Several kinds of muscular dystrophies and dystrophy-like myopathies have also been described in companion animals (Shelton and Engvall 2002, Shelton 2004, Blot 2005, Gaschen and Jones 2005, Shelton and Engvall 2005). The muscular dystrophies whose causes have been identified are dystrophinopathy and laminin α2 deficiency in dogs and cats, and saccoglycanopathies in dogs (Cooper et al. 1988, Kornegay et al. 1988, Valentine et al. 1988, Carpenter et al. 1989, Gaschen et al. 1992, Gaschen and Burgunder 2001, O’Brien et al. 2001, Shelton et al. 2001, Poncelet et al. 2003, Shelton and Engvall 2005). Muscular dystrophy with dystrophinopathy in cats, which is similar to Duchenne muscular dystrophy in humans, generally occurs in males as an X chromosome-linked disorder (Carpenter et al. 1989, Gaschen et al. 1992, Gaschen and Burgunder 2001). It is characterised by systemic muscle hypertrophy and is known as hypertrophic feline muscular dystrophy (Gaschen et al. 1992, Gaschen and Burgunder 2001, Gaschen et al. 2004). Muscular dystrophy with laminin α2 deficiency in cats has been reported in three females, and the disease was not familial (O’Brien et al. 2001, Poncelet et al. 2003).

In cats with laminin α2-deficient muscular dystrophy, muscle atrophy and joint contracture have been described (O’Brien et al. 2001, Poncelet et al. 2003). These two signs were evident in the present cat. It is considered that muscle atrophy and joint contracture are characteristic clinical features of the disease, differing from those of hypertrophic feline muscular dystrophy. Although the present cat showed no evident neurological abnormality, peripheral nerve involvement has been described in three cats with laminin α2-deficient muscular dystrophy and also in merosin-deficient congenital muscular dystrophy in humans (Shorer et al. 1995, O’Brien et al. 2001, Poncelet et al. 2003). In the present case pathological examinations of the nervous system were performed using only paraffin sections, and further specific investigations including ultrastructural studies would be needed to evaluate the morphological changes in the peripheral nerves. Cardiac changes similar to those of hypertrophic cardiomyopathy were recognised in the present cat. The relationship between the cardiac lesions and laminin α2 deficiency remains unclear, as the cardiac changes have not been described in previously reported cats with laminin α2-deficient muscular dystrophy (O’Brien et al. 2001, Poncelet et al. 2003). Although the present cat showed a tendency for urine retention, no pathological changes which could have caused dysuria were identified.

In the present case, the cause of death was presumed to be aspiration pneumonia because of the clinical signs, and the findings of necropsy and pathological examination. The disease progression in cats with laminin α2-deficient muscular dystrophy is not clear, as all three other reported cats were euthanased before 2 years of age (O’Brien et al. 2001, Poncelet et al. 2003). In humans with merosin-deficient congenital muscular dystrophy, the major cause of death is respiratory tract infection (Hayashi and Arahata 1997). As this cat was not euthanased the case history should provide additional information on the clinical course of this disease.

The present cat was the product of inbreeding, and had a sibling with similar signs as well as four normal siblings, which is consistent with recessive inheritance. As laminin α2-deficient muscular dystrophy occurs in both male (the present case) and female (previously reported cases) cats, the disease is consistent with an autosomal recessive inheritance.

To the authors’ knowledge, this is the first report of laminin α2-deficient muscular dystrophy in a male cat, and the first to suggest a familial origin in this species. Most importantly, this is the first report to describe the clinical progression and course of this disease in a cat.

Acknowledgements
The authors thank Takuo Ishida DVM, PhD, from Idexx Laboratories, Tokyo, Japan, for performing the dystrophin analysis on the biopsy.
References

Blot S (2005) Disorders of the skeletal muscles — canine. In: Ettinger SJ, Feldman EC (eds), Textbook of Veterinary Internal Medicine (6th edn). St Louis: Elsevier Saunders, pp. 501–509.

Carpenter JL, Hoffman EP, Romanul FC, Kunkel LM, Rosales RK, Ma NS, Dasbach JJ, Rae JE, Moore FM, McAfee MB, Pearce LK (1989) Feline muscular dystrophy with dystrophin deficiency. *American Journal of Pathology* **135**, 909–919.

Cooper BJ, Valentine BA, Wilson S, Patterson DF, Concannon PW (1988) Canine muscular dystrophy: confirmation of X-linked inheritance. *Journal of Heredity* **79**, 405–408.

Emery AE (2001a) Muscular dystrophy — an evolving concept. In: Emery AE (ed), *The Muscular Dystrophies*. New York: Oxford University Press, pp. 1–9.

Emery AE (2001b) Congenital muscular dystrophies. In: Emery AE (ed), *The Muscular Dystrophies*. New York: Oxford University Press, pp. 10–38.

Gaschen FP, Hoffman EP, Gorospe JR, Uhl EW, Senior DF, Cardinet GH, Pearce LK (1992) Dystrophin deficiency causes lethal muscle hypertrophy in cats. *Journal of the Neurological Sciences* **110**, 149–159.

Gaschen F, Burgunder JM (2001) Changes of skeletal muscle in young dystrophin-deficient cats: a morphological and morphometric study. *Acta Neuropathologica* **101**, 591–600.

Gaschen F, Jaggy A, Jones B (2004) Congenital diseases of feline muscle and neuromuscular junction. *Journal of Feline Medicine and Surgery* **6**, 355–366.

Gaschen FP, Jones BR (2005) Feline myopathies. In: Ettinger SJ, Feldman EC (eds), Textbook of Veterinary Internal Medicine (6th edn). St Louis: Elsevier Saunders, pp. 906–912.

Hayashi YK, Arahata K (1997) Congenital muscular dystrophy. *No To Shinkei* **49**, 311–318.

Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tome FM, Schwartz K, Fardeau M, Tryggvason K, Guicheney P (1995) Mutations in the laminin a2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. *Nature Genetics* **11**, 216–218.

Kornegay JN, Tuler SM, Miller DM, Levesque DC (1988) Muscular dystrophy in a litter of golden retriever dogs. *Muscle and Nerve* **11**, 1056–1064.

Leivo I, Engvall E (1988) Merosin, a protein specific for basement membranes of Schwann cells, striated muscle, and trophoblast, is expressed late in nerve and muscle development. *Proceedings of the National Academy of Sciences of the United States of America* **85**, 1544–1548.

O’Brien DP, Johnson GC, Liu LA, Guo LT, Engvall E, Powell HC, Shelton GD (2001) Laminin alpha 2 (merosin)-deficient muscular dystrophy and demyelinating neuropathy in two cats. *Journal of the Neurological Sciences* **189**, 37–43.

Poncelet L, Resibois A, Engvall E, Shelton GD (2003) Laminin alpha2 deficiency-associated muscular dystrophy in a Maine coon cat. *Journal of Small Animal Practice* **44**, 550–552.

Shelton GD, Liu LA, Guo LT, Smith GK, Christiansen JS, Thomas WB, Smith MO, Kline KL, March PA, Flegel T, Engvall E (2001) Muscular dystrophy in female dogs. *Journal of Veterinary Internal Medicine* **15**, 240–244.

Shelton GD, Engvall E (2002) Muscular dystrophy and other inherited myopathies. *Veterinary Clinics of North America: Small Animal Practice* **32**, 103–124.

Shelton GD (2004) Muscular dystrophies: expanding our knowledge in companion animals. *Veterinary Journal* **168**, 6–8.

Shelton GD, Engvall E (2005) Canine and feline models of human inherited muscle diseases. *Neuromuscular Disorders* **15**, 127–138.

Shorer Z, Philpot J, Muntoni F, Sewry C, Dubowitz V (1995) Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. *Journal of Child Neurology* **10**, 472–475.

Tome FM, Evangelista T, Leclerc A, Sunada Y, Manole E, Estournet B, Barois A, Campbell KP, Fardeau M (1994) Congenital muscular dystrophy with merosin deficiency. *Comptes Rendus de l’Academie des Sciences III* **317**, 351–357.

Valentine BA, Cooper BJ, de Lahunta A, O’Quinn R, Blue JT (1988) Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. *Journal of the Neurological Sciences* **88**, 69–81.

Wewer UM, Engvall E (1996) Merosin/laminin-2 and muscular dystrophy. *Neuromuscular Disorders* **6**, 409–418.